Cargando…

Schneider’s first-rank symptoms as predictors of remission in antipsychotic-naive first-episode psychosis

OBJECTIVE: German psychiatrist Kurt Schneider proposed the concept of first-rank symptoms (FRS) of schizophrenia in 1959. However, their relevance for diagnosis and prediction of treatment response are still unclear. Most studies have investigated FRS in chronic or medicated patients. The present st...

Descripción completa

Detalles Bibliográficos
Autores principales:	Malinowski, Fernando R., Tasso, Brazilio de C., Ortiz, Bruno B., Higuchi, Cinthia H., Noto, Cristiano, Belangero, Sintia I., Bressan, Rodrigo A., Gadelha, Ary, Cordeiro, Quirino
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Associação Brasileira de Psiquiatria 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6986488/ https://www.ncbi.nlm.nih.gov/pubmed/31166544 http://dx.doi.org/10.1590/1516-4446-2018-0237

Ejemplares similares

O8.2. DURATION OF UNTREATED PSYCHOSIS (DUP) IS ASSOCIATED WITH WORSE RESPONSE TO TREATMENT IN ANTIPSYCHOTIC NAïVE FIRST EPISODE PSYCHOSIS
por: Cavalcante, Daniel, et al.
Publicado: (2018)

T97. CANNABIS USE IMPACTS SYMPTOM PRESENTATION IN ANTIPSYCHOTIC NAIVE PATIENTS IN FIRST EPISODE OF PSYCHOSIS (FEP)
por: Coutinho, Luccas, et al.
Publicado: (2018)

Hair cortisol in drug-naïve first-episode individuals with psychosis
por: Andrade, Elvis H., et al.
Publicado: (2016)

T121. BLUNTED AFFECT EARLY PROGRESSION IN DRUG-NAïVE FIRST EPISODE SCHIZOPHRENIA PATIENTS: 10-WEEK FOLLOW UP
por: Kagan, Simão, et al.
Publicado: (2020)

Polygenic risk score analyses of symptoms and treatment response in an antipsychotic-naive first episode of psychosis cohort
por: Santoro, Marcos Leite, et al.
Publicado: (2018)

A Study in First-Episode Psychosis Patients: Does Angiotensin I-Converting Enzyme Activity Associated With Genotype Predict Symptom Severity Reductions After Treatment With Atypical Antipsychotic Risperidone?
por: Nani, João V, et al.
Publicado: (2020)

Effects of Risperidone on Cytokine Profile in Drug-Naïve First-Episode Psychosis
por: Noto, Cristiano, et al.
Publicado: (2015)

F119. MULTILEVEL ANALYSIS IMPROVES THE MODEL FIT OF THE DIMENSIONAL STRUCTURE OF THE PANSS IN PATIENTS WITH SCHIZOPHRENIA
por: Higuchi, Cinthia, et al.
Publicado: (2018)

Schneider’s first-rank symptoms and treatment outcome
por: Massuda, Raffael
Publicado: (2020)

T119. NO DIFFERENCE BETWEEN VOLITIVE AND EXPRESSIVE NEGATIVE SYMPTOMS FOR EARLY TREATMENT RESPONSE IN FIRST EPISODE OF PSYCHOSIS ANTIPSYCHOTIC NAïVE PATIENTS
por: Haguiara, Bernardo, et al.
Publicado: (2020)

T117. INVESTIGATION OF FORMAL THOUGHT DISORDER AND RESPONSE TO TREATMENT IN SCHIZOPHRENIA
por: Loures Malinowski, Fernando Rocha, et al.
Publicado: (2018)

A STUDY OF FIRST RANK SYMPTOMS OF SCHNEIDER IN FUNCTIONAL PSYCHOSES*
por: Raguram, R., et al.
Publicado: (1985)

T100. NICOTINE USE IMPACTS NEGATIVE SYMPTOMS SEVERITY IN SCHIZOPHRENIA
por: Oliveira, Hianna, et al.
Publicado: (2018)

The role of the CNR1 gene in schizophrenia: a systematic review including unpublished data
por: Gouvêa, Eduardo S., et al.
Publicado: (2017)

S128. CORRELATION OF DURATION OF UNTREATED PSYCHOSIS WITH TREATMENT RESPONSE ON THE SYMPTOM DIMENSIONS OF SCHIZOPHRENIA
por: Elias, Beatriz Yukie, et al.
Publicado: (2018)

S129. DOES TREATMENT RESISTANT SCHIZOPHRENIA PRESENT A CHARACTERISTIC SYMPTOMATIC SIGNATURE?
por: Bertolucci, Bruno, et al.
Publicado: (2018)

T176. REDUCED WHITE MATTER ‘CONNECTIVITY’ IN THE SPLENIUM OF THE CORPUS CALLOSUM IN TREATMENT-RESISTANT SCHIZOPHRENIA
por: Assunção-Leme, Idaiane, et al.
Publicado: (2018)

S174. POLYENVIRONMENTAL AND POLYGENIC RISK SCORES AND THE EMERGENCE OF PSYCHOTIC EXPERIENCES IN CHILDREN AND ADOLESCENTS
por: Belangero, Sintia, et al.
Publicado: (2020)

Using deep belief network modelling to characterize differences in brain morphometry in schizophrenia
por: Pinaya, Walter H. L., et al.
Publicado: (2016)

Pars Triangularis Volume Asymmetry and Schneiderian First Rank Symptoms in Antipsychotic-naïve Schizophrenia
por: Shivakumar, Venkataram, et al.
Publicado: (2021)

Gene expression over the course of schizophrenia: from clinical high-risk for psychosis to chronic stages
por: Ota, Vanessa Kiyomi, et al.
Publicado: (2019)

COVID-19 contamination and severity among patients with schizophrenia: Results from a specialized outpatient clinic survey
por: Costardi, Carlos Gustavo, et al.
Publicado: (2022)

Relationship between Brain-Derived Neurotrophic Factor and Schneiderian First Rank Symptoms in Antipsychotic-Naïve Schizophrenia
por: Kalmady, Sunil Vasu, et al.
Publicado: (2013)

Childhood trauma, antipsychotic medication, and symptom remission in first-episode psychosis
por: Ottesen, Akiah, et al.
Publicado: (2023)

Applying polygenic risk scoring for psychiatric disorders to a large family with bipolar disorder and major depressive disorder
por: de Jong, Simone, et al.
Publicado: (2018)

Diversity matters: opportunities in the study of the genetics of psychotic disorders in low- and middle-income countries in Latin America
por: Fonseca, Lais, et al.
Publicado: (2020)

How challenging is to manage agitated patients?
por: Cavalcante, Daniel A., et al.
Publicado: (2019)

Evaluation of the efficacy of transcranial direct current stimulation in the treatment of cognitive symptomatology in the early stages of psychosis: study protocol for a double-blind randomized controlled trial
por: Rabanea-Souza, Thais, et al.
Publicado: (2019)

Catechol-O-methyltransferase (COMT) polymorphisms modulate working memory in individuals with schizophrenia and healthy controls
por: Matsuzaka, Camila T., et al.
Publicado: (2017)

Linkage Replication for Chromosomal Region 13q32 in Schizophrenia: Evidence from a Brazilian Pilot Study on Early Onset Schizophrenia Families
por: Gadelha, Ary, et al.
Publicado: (2012)

Inferior Parietal Lobule Volume and Schneiderian First-Rank Symptoms in Antipsychotic-Naïve Schizophrenia: A 3-Tesla MRI Study
por: Danivas, Vijay, et al.
Publicado: (2009)

M200. CLOZAPINE-INDUCED HEPATOTOXICITY: TWO CASE REPORTS
por: Dias, Cintia, et al.
Publicado: (2020)

Alimentation S.W. (Schneider—Westinghouse)
por: Boimond, D
Publicado: (1976)

In memoriam: Francisc Schneider (1933‐2017)
por: Păunescu, Virgil, et al.
Publicado: (2019)

Dr. Cral Von Arx Schneider
Publicado: (1917)

Remission from antipsychotic treatment in first episode psychosis related to longitudinal changes in brain glutamate
por: Merritt, Kate, et al.
Publicado: (2019)

Gene expression alterations related to mania and psychosis in peripheral blood of patients with a first episode of psychosis
por: Gouvea, E S, et al.
Publicado: (2016)

Negative dimension stability across clinical stages and sociodemographic characteristics in schizophrenia
por: Koga, Gabriela, et al.
Publicado: (2022)

Clozapine prescription trends in Brazil in the last decade
por: Massuda, Raffael, et al.
Publicado: (2022)

Maintenance antipsychotic treatment versus discontinuation strategies following remission from first episode psychosis: systematic review
por: Thompson, Andrew, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_27q8asc2jof0bpcl6l6uk7nr0h